CA2953170A1 - Methods of treating or ameliorating migraine - Google Patents

Methods of treating or ameliorating migraine Download PDF

Info

Publication number
CA2953170A1
CA2953170A1 CA2953170A CA2953170A CA2953170A1 CA 2953170 A1 CA2953170 A1 CA 2953170A1 CA 2953170 A CA2953170 A CA 2953170A CA 2953170 A CA2953170 A CA 2953170A CA 2953170 A1 CA2953170 A1 CA 2953170A1
Authority
CA
Canada
Prior art keywords
migraine
patient
compound
administering
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2953170A
Other languages
English (en)
French (fr)
Inventor
Joseph R. Moskal
Patric STANTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Naurex Inc
Original Assignee
Northwestern University
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University, Naurex Inc filed Critical Northwestern University
Publication of CA2953170A1 publication Critical patent/CA2953170A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2953170A 2014-06-23 2015-06-23 Methods of treating or ameliorating migraine Abandoned CA2953170A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462015727P 2014-06-23 2014-06-23
US62/015,727 2014-06-23
US201562109386P 2015-01-29 2015-01-29
US62/109,386 2015-01-29
PCT/US2015/037177 WO2015200322A1 (en) 2014-06-23 2015-06-23 Methods of treating or ameliorating migraine

Publications (1)

Publication Number Publication Date
CA2953170A1 true CA2953170A1 (en) 2015-12-30

Family

ID=54938737

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953170A Abandoned CA2953170A1 (en) 2014-06-23 2015-06-23 Methods of treating or ameliorating migraine

Country Status (10)

Country Link
EP (1) EP3157943A4 (https=)
JP (2) JP6688748B2 (https=)
KR (1) KR20170018072A (https=)
CN (1) CN106661085A (https=)
AU (1) AU2015280108B2 (https=)
BR (1) BR112016030375A8 (https=)
CA (1) CA2953170A1 (https=)
MX (1) MX2016017388A (https=)
RU (1) RU2721401C2 (https=)
WO (1) WO2015200322A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7476229B2 (ja) * 2019-04-15 2024-04-30 フェリン・ファーマシューティカルズ・インコーポレイテッド 片頭痛の治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006468A1 (en) * 1993-09-01 1995-03-09 Smithkline Beecham Corporation Method for treating migraine headaches
DE60131032T2 (de) * 2000-08-25 2008-08-14 Research Corp. Technologies, Inc., Tucson Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
EP1337559A2 (en) * 2000-11-17 2003-08-27 Bayer Ag Regulation of human nmda receptor
ES2381091T3 (es) * 2003-03-06 2012-05-23 Botulinum Toxin Research Associates, Inc. Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica
NZ590793A (en) * 2008-07-23 2012-07-27 Kyowa Hakko Kirin Co Ltd Therapeutic agent for migraine
WO2011003064A2 (en) * 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
PL2485751T3 (pl) * 2009-10-05 2014-10-31 Univ Northwestern GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
CN105037492A (zh) * 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
US20140107037A1 (en) * 2011-04-27 2014-04-17 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
US20150253305A1 (en) * 2012-10-12 2015-09-10 Northwestern University Methods of identifying compounds for treating depression and other related diseases

Also Published As

Publication number Publication date
BR112016030375A2 (pt) 2017-08-15
JP2017519778A (ja) 2017-07-20
MX2016017388A (es) 2018-02-19
RU2017101410A3 (https=) 2019-01-21
CN106661085A (zh) 2017-05-10
AU2015280108B2 (en) 2019-11-28
BR112016030375A8 (pt) 2021-07-13
KR20170018072A (ko) 2017-02-15
RU2017101410A (ru) 2018-07-24
WO2015200322A1 (en) 2015-12-30
JP2020114863A (ja) 2020-07-30
AU2015280108A1 (en) 2017-01-19
EP3157943A4 (en) 2018-01-24
RU2721401C2 (ru) 2020-05-19
EP3157943A1 (en) 2017-04-26
JP6688748B2 (ja) 2020-04-28

Similar Documents

Publication Publication Date Title
ES2750728T3 (es) Uso de cannabinoides en combinación con Aripriprazol
ES2791764T3 (es) Composiciones de buprenorfina y antagonistas del receptor de opioides mu
US20090163451A1 (en) Methods for treating visceral pain
Yin et al. Paeoniflorin exerts analgesic and hypnotic effects via adenosine A1 receptors in a mouse neuropathic pain model
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
US11419857B2 (en) Methods and compositions for treating pain
AU2015280108B2 (en) Methods of treating or ameliorating migraine
ES2734066T3 (es) Samidorfano (ALKS 33) en combinación con agonistas opioides
ES2362926T3 (es) Nueva combinación de fármacos como un antidepresivo.
JP2012102069A (ja) 早漏治療剤
US20250205205A1 (en) Methods and compositions for preventing and treating fibrosis and improving functional recovery after injury or with aging
KR20250121164A (ko) 치료법 및 화장품에 사용하기 위한 sarm1 제제
Blackshaw Selective Role for TRPV4 Ion Channels in Visceral Sensory Pathways
Chang Dopamine D3 regulation of sensorimotor gating
Woodall Actions of two intravenous anaesthetic agents, propofol and ketamine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200611

FZDE Discontinued

Effective date: 20221115